Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.23 (
MMP
)
4,246
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Invasion of cancer cells into collagen-rich extracellular matrix requires membrane-tethered membrane type 1-matrix metalloproteinase (MT1-MMP) as the key protease for collagen breakdown. Understanding how MT1-
MMP
is delivered to the surface of tumor cells is essential for cancer cell biology. In this study, we identify ARF6 together with c-Jun NH2-terminal kinase-interacting protein 3 and 4 (JIP3 and JIP4) effectors as critical regulators of this process. Silencing ARF6 or JIP3/JIP4 in breast tumor cells results in MT1-
MMP
endosome mispositioning and reduces MT1-
MMP
exocytosis and tumor cell invasion. JIPs are recruited by Wiskott-Aldrich syndrome protein and scar homologue (WASH) on MT1-
MMP
endosomes on which they recruit dynein-dynactin and kinesin-1. The interaction of plasma membrane ARF6 with endosomal JIPs coordinates dynactin-dynein and kinesin-1 activity in a tug-of-war mechanism, leading to MT1-
MMP
endosome tubulation and exocytosis. In addition, we find that ARF6, MT1-
MMP
, and kinesin-1 are up-regulated in high-grade triple-negative breast cancers. These data identify a critical ARF6-
JIP
-MT1-
MMP
-dynein-dynactin-kinesin-1 axis promoting an invasive phenotype of breast cancer cells.
...
PMID:ARF6-JIP3/4 regulate endosomal tubules for MT1-MMP exocytosis in cancer invasion. 2650 63